Colinz Laboratories
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
The Dugar family launched a mandatory open offer to acquire up to 26% of Colinz Laboratories at ₹54 per share, valuing the offer at ₹3.54 crore. The bid follows a share purchase agreement to buy a 34.56% stake from promoter Vijaya Mani at ₹50 per share for ₹4.35 crore. The combined transaction will hand control of the Mumbai-based pharmaceutical company to Annjana Dugar, Likhitta Dugar, Antariksh Dugar, and their PAC Padam Dugar, who together held 15.01% before the deal.
Powered by Tijori
The Dugar family launched a mandatory open offer to acquire up to 26% of Colinz Laboratories at ₹54 per share, valuing the offer at ₹3.54 crore. The bid follows a share purchase agreement to buy a 34.56% stake from promoter Vijaya Mani at ₹50 per share for ₹4.35 crore. The combined transaction will hand control of the Mumbai-based pharmaceutical company to Annjana Dugar, Likhitta Dugar, Antariksh Dugar, and their PAC Padam Dugar, who together held 15.01% before the deal.
Powered by Tijori
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Colinz Laboratories do?
Colinz Laboratories Ltd manufactures a wide range of pharmaceutical formulations, including tablets, capsules, creams, and veterinary and nutraceutical products. They also provide turnkey projects for pharma formulation plants and technical know-how transfer.
Who are the competitors of Colinz Laboratories?
Colinz Laboratories major competitors are Kobo Biotech, Zenith Health Care, Omkar Pharmachem, Norris Medicines, Starsource Multitrad, Ortin Global, Desh Rakshak Aushdh. Market Cap of Colinz Laboratories is ₹17 Crs. While the median market cap of its peers are ₹17 Crs.
Is Colinz Laboratories financially stable compared to its competitors?
Colinz Laboratories seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Colinz Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Colinz Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Colinz Laboratories allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Colinz Laboratories balance sheet?
Balance sheet of Colinz Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Colinz Laboratories improving?
Yes, profit is increasing. The profit of Colinz Laboratories is ₹0.51 Crs for TTM, ₹0.5 Crs for Mar 2025 and ₹0.49 Crs for Mar 2024.
Is the debt of Colinz Laboratories increasing or decreasing?
Yes, The net debt of Colinz Laboratories is increasing. Latest net debt of Colinz Laboratories is -₹8.14 Crs as of Mar-26. This is greater than Mar-25 when it was -₹10.45 Crs.
Is Colinz Laboratories stock expensive?
Yes, Colinz Laboratories is expensive. Latest PE of Colinz Laboratories is 33.66, while 3 year average PE is 26.78. Also latest EV/EBITDA of Colinz Laboratories is 21.72 while 3yr average is 11.16.
Has the share price of Colinz Laboratories grown faster than its competition?
Colinz Laboratories has given better returns compared to its competitors. Colinz Laboratories has grown at ~17.17% over the last 8yrs while peers have grown at a median rate of 3.6%
Is the promoter bullish about Colinz Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Colinz Laboratories is 66.0% and last quarter promoter holding is 66.0%.
Are mutual funds buying/selling Colinz Laboratories?
There is Insufficient data to gauge this.